【ChiCTR2500107057】Effectiveness of an immersive virtual reality (VR)-based mindfulness intervention (MI) to reduce depressive symptoms in patients with autoimmune arthritis (AA): a randomized control trial (RCT)
ChiCTR2500107057
尚未开始
/
/
/
2025-08-01
/
/
Autoimmune arthritis
Effectiveness of an immersive virtual reality (VR)-based mindfulness intervention (MI) to reduce depressive symptoms in patients with autoimmune arthritis (AA): a randomized control trial (RCT)
Effectiveness of an immersive virtual reality (VR)-based mindfulness intervention (MI) to reduce depressive symptoms in patients with autoimmune arthritis (AA): a randomized control trial (RCT)
/
To evaluate the effectiveness of an immersive VR-based mindfulness intervention program in reducing depressive symptoms among patients with autoimmune arthritis.
随机平行对照
治疗新技术
Eligible subjects will be individually randomized to the intervention or control group (1:1) using sequentially numbered, opaque, sealed envelopes (SNOSE), and block randomization. A statistician who is not part of the research team will generate the random numbers and assignment and prepare 198 identical opaque sealed A5-sized envelopes. The block randomization list will be created with a 1:1 allocation ratio and block size of 4, 8 and 12 in random order to ensure that a similar number of participants will be allocated to both groups.
Given the apparent nature of the intervention, it is unlikely to blind participants and intervention providers.
The Kadoorie Charitable Foundation Grant & Hong Kong Metropolitan University
/
99
/
2025-01-01
2027-02-28
/
Patients with AA aged 18 or above will be eligible. The inclusion criteria are: 1. being able to communicate in Cantonese, 2. presenting with depressive symptoms over the past two weeks based on the established criteria (DSM V) with a Patient Health Questionniare-9 score of at least five or above, 3. being able to commit to six consecutive weekly VR-based mindfulness sessions, and 4. on a stable medication regimen.;
请登录查看1. Severe visual or auditory deficits. 2. Severe organic disease or malignant tumour. 3. A history of motion or simulator sickness. 4. History of epilepsy. 5. A recent mental disorder in the past 12 months or current psychiatric disorder that are potentially life threatening (i.e. psychosis, suicidal ideation). 6. Meditation and yoga practice within the past 6 months or will plan to start mindfulness intervention.;
请登录查看School of Nursing and Health Sciences, Hong Kong Metropolitan University
/
/
School of Nursing and Health Sciences, Hong Kong Metropolitan University的其他临床试验
School of Nursing and Health Sciences, Hong Kong Metropolitan University的其他临床试验
最新临床资讯
-
一项5年临床安全随访研究启示:#脐带间充质干细胞(#hUC-MSCs)
SCLnow圣释2026-11-11
-
SYNCHRONIZE-CVOT试验达到主要终点,索弗度肽(survodutide)成为全球首个证实心血管安全性的胰高血糖素/GLP-1双受体激动剂
勃林格殷格翰中国2026-11-11
-
医药观澜2026-11-11
-
宜明昂科2026-11-11
-
医学科学院精准医学研究所2026-11-11
-
多肽圈2026-11-11
-
多肽圈2026-11-11
-
求是网2026-11-11
-
干细胞之父2026-11-11
-
和田维药2026-11-11
全球药物研发中心
全球研发数据与行业前沿情报
-
2026-11-12
-
2026-11-12
-
2026-11-12
-
摩熵咨询 20 3
-
摩熵咨询 33 60
-
摩熵咨询 20 3
-
颁布机构:国家卫生健康委办公厅、 2026-11-10
-
颁布机构:国家卫健委(原国家卫计委) 2026-11-10
-
颁布机构:国家药品审评中心(CDE) 2026-10-16
医药市场洞察中心
医药市场销售数据分析 · 智能洞察 · 竞争格局监测
-
医药市场销售数据分析 · 医院、实体药店、网上药店
-
市场竞争格局分析(靶点、药品类型、ATC大类)
-
2026-11-11
-
2026-11-11
-
2026-11-11
-
摩熵咨询 35 92
-
摩熵咨询 28 74
-
摩熵咨询 34 49
-
颁布机构:国家市场监督管理总局 2026-11-07
-
颁布机构:国家市场监督管理总局 2026-11-07
-
颁布机构:国家市场监督管理总局 2026-11-04

